Biocon’s Avastin Biosimilar To Put The Heat On Competition?

Biocon has launched its biosimilar Avastin in India, intensifying competition on the market. In addition to its ‘affordable’ price, Biocon’s biosimilar Avastin also comes with a novel temperature-sensitive packaging, which it sees as a key differentiator. Roche meanwhile underscored the need to be “very careful” while making packaging changes with biologics.

Profit
BIOCON HAS LAUNCHED ITS CUT-PRICE AVASTIN BIOSIMILAR • Source: Shutterstock

India’s largest biopharmaceutical company, Biocon Ltd., has introduced its biosimilar Avastin (bevacizumab) on the domestic market, backed by a strategy that seeks to move beyond price competition.

While Biocon’s Krabeva appears to be priced along similar lines as the biosimilar bevacizumab from competitor Intas Pharmaceuticals Ltd.,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip